 EVANSTON, Ill.--BUSINESS WIRE--Aptinyx Inc. Nasdaq: APTX, a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the appointment of Andy Kidd, the companys current chief operating officer, to the role of president and chief operating officer, effective December 14, 2020. We are thrilled to have Andy expand his role as president and chief operating officer, given his strong commitment to our co 